726,582 Shares in OPKO Health, Inc. (NASDAQ:OPK) Purchased by Clearline Capital LP

Clearline Capital LP purchased a new stake in shares of OPKO Health, Inc. (NASDAQ:OPK) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 726,582 shares of the biotechnology company’s stock, valued at approximately $1,083,000. Clearline Capital LP owned approximately 0.11% of OPKO Health at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. CIBC Asset Management Inc grew its stake in shares of OPKO Health by 79.1% in the 2nd quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock worth $25,000 after buying an additional 8,978 shares in the last quarter. FMR LLC lifted its holdings in shares of OPKO Health by 103.6% in the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 11,089 shares during the last quarter. Virtu Financial LLC purchased a new position in OPKO Health in the first quarter worth about $26,000. Algert Global LLC purchased a new position in OPKO Health in the second quarter worth about $44,000. Finally, Private Advisor Group LLC increased its stake in OPKO Health by 242.7% during the third quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 25,000 shares during the last quarter. Institutional investors own 64.63% of the company’s stock.

OPKO Health Trading Down 2.5 %

Shares of NASDAQ OPK opened at $1.54 on Monday. OPKO Health, Inc. has a fifty-two week low of $0.85 and a fifty-two week high of $1.75. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The company has a market cap of $1.05 billion, a price-to-earnings ratio of -8.11 and a beta of 1.65. The business’s 50 day moving average price is $1.52 and its 200-day moving average price is $1.46.

Analyst Ratings Changes

Several research firms have recently weighed in on OPK. HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of OPKO Health in a research report on Thursday, September 26th. Barrington Research reiterated an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a research report on Friday, November 8th. Finally, Piper Sandler restated an “overweight” rating and issued a $3.00 target price on shares of OPKO Health in a report on Tuesday, September 17th.

Insiders Place Their Bets

In related news, CEO Phillip Md Et Al Frost bought 199,072 shares of the company’s stock in a transaction on Friday, November 29th. The shares were acquired at an average cost of $1.53 per share, for a total transaction of $304,580.16. Following the purchase, the chief executive officer now directly owns 211,911,477 shares of the company’s stock, valued at approximately $324,224,559.81. The trade was a 0.09 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have acquired a total of 679,255 shares of company stock worth $1,045,855 over the last quarter. Company insiders own 47.26% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.